Friday, 22 Mar 2019

You are here

mTOR Inhibition with Sirolimus Effective in Lupus

Lancet reports that 12 months of sirolimus treatment is associated with improvement in lupus disease activity presumeably by correction of pro-inflammatory T-cell activity.

Systemic lupus erythematosus (SLE) oatients are known to have T-cell dysfunction attributed to the activation of the mammalian target of rapamycin (mTOR). Rapamycin inhibits antigen-induced T-cell proliferation and has been developed as a medication under the generic designation of sirolimus. Researchers investigated the efficacy, safety, and tolerance of sirolimus in a prospective, open-label trial.

A single-arm, open-label study of 40 active SLE patients, unresponsive or intolerant of conventional therapy were given oral sirolimus 2 mg per day, with dose adjustments to achieve a therapeutic range of 6–15 ng/mL. The primary endpoint was decrease in disease activity, assessed using the British Isles Lupus Assessment Group (BILAG) index and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).

The study was hampered by high dropout and discontinuations. Of the 40, 11 discontinued treatment for intolerance (n=2) or noncompliance (n=9).  In the remaining 29 patients only 16 (37.5% of the original cohort) completed 12 months of therapy.

Clinical (SLEDAI and BILAG) and immunological improvements were seen over 12 months:

  • SLEDAI score decreased from 10·2 to 4·8 (p<0·001)
  • Total BILAG index score decreased from 28·4 to 17·4 (p<0·001)
  • Mean prednisone dose decreased from 23·7 mg to 7·2 mg (p<0·001)
  • Increased CD4+CD25+FoxP3+ regulatory T cells
  • Increased CD8+ memory T-cell populations
  • Inhibited interleukin-4 and interleukin-17 production by CD4+ and CD4−CD8− double-negative T cells

Safety parameters (liver function and lymphocyte counts) were largely unchanged and modest reductions in HDL-cholesterol  neutrophil counts and hemoglobin and slight increases in platelet counts were observed.

mTOR blockade with sirolimus appears to be effective in a subset of active systemic lupus erythematosus.patients. Larger studies are needed to better determine the ideal candidates or measures to improve compliance and tolerability.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

Single arm, open label, high dropout. That pretty much tells us how much trust we can put in this study. Lancet apparently continues its tradition of publishing great sounding studies of low scientific quality.

More Like This

Resistant Hypertension Common in SLE

Rates of resistant hypertension were doubled among patients with systemic lupus erythematosus (SLE), significantly increasing their mortality risks, a retrospective single-center study found.

Among patients with SLE, the prevalence of resistant hypertension was 10.2% compared with 5.3% among controls (OR 2.02, 95% CI 1.60-2.55, P<0.0001), according to Cecilia P. Chung, MD, and colleagues from Vanderbilt University in Nashville.

Improved Mortality Trends in Lupus Nephritis

The mortality rate from end- stage renal disease (ESRD) in lupus nephritis (LN) patients has significantly decreased in the last decade.

Cyclosporin and IVIG Effective in Kawasaki's Disease

A Lancet study has shown that adding cyclosporin to intravenous immunoglobulin (IVIG) Kawasaki disease patients, who were predicted to be resistant to IVIG, was both safe and effective in averting severe coronary artery outcomes.

Brazilian Guidelines for Systemic Autoimmune Myopathies

The Myopathy Committee of the Brazilian Society of Rheumatology (BSR) has put forward recommendations for the management of patients with systemic autoimmune myopathies (SAM).

The challenge has been that there is a paucity of effective controlled clinical trials, and hence, glucocorticoids (GC) have played a first-line and prominent role in the treatment of SAM.

EULAR Consensus Guidelines for Juvenile Localized Scleroderma

A EULAR international committee of 15 experts in pediatric rheumatology have established consensus-based recommendations for the management of juvenile localised scleroderma (JLS).

JLS is an uncommon disorder that is commonly seen by pediatric and adult rheumatologists. Evidence-based guidelines are sparse and management is mostly based on physicians’ experience.